Withdrawals due to adverse events · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors leads to lower withdrawal due to adverse effects compared with all angiotensin receptor blockers (ARBs) (high certainty).
1 finding from 1 review
Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · adults with primary hypertension
1 finding from 1 review
Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · adults with primary hypertension
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 2.5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 10 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 20 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 40 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
WDAE2 all doses · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
SBP
1 finding from 1 review
no estimate extracted
3206 participants
High
Intervention not reported
DBP
1 finding from 1 review
no estimate extracted
3230 participants
High
Intervention not reported
Total mortality Systolic targets · Diabetes Mellitus with elevated blood pressure
The intervention showed no clear difference in total mortality Systolic targets (low certainty).
1 finding from 1 review
Intervention not reported
Total mortality Diastolic targets · Diabetes Mellitus with elevated blood pressure
It is very uncertain whether the intervention changes total mortality Diastolic targets (very low certainty).
1 finding from 1 review
Intervention not reported
Total serious adverse events Systolic targets · Diabetes Mellitus with elevated blood pressure
The intervention showed no clear difference in total serious adverse events Systolic targets (low certainty).
1 finding from 1 review
Intervention not reported
Mortality 4 to 5 years · Adults with mild hypertension and no cardiovascular disease
It is very uncertain whether the intervention changes mortality 4 to 5 years (very low certainty).
1 finding from 1 review
Intervention not reported
Total CV events 5 years · Adults with mild hypertension and no cardiovascular disease
It is very uncertain whether the intervention changes total CV events 5 years (very low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse effects 5 years · Adults with mild hypertension and no cardiovascular disease
The intervention probably leads to higher withdrawals due to adverse effects 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Creatine phosphate 1g/day · patients with heart failure
1 finding from 1 review
Intervention not reported
Creatine 20g/day for 6 weeks · patients with heart failure
1 finding from 1 review
Intervention not reported
Creatine 20g/day for 10 days · patients with heart failure
1 finding from 1 review